Koers BioSyent Inc. Other OTC
Aandelen
BIOYF
CA0906901081
Farmaceutische producten
Omzet 2024 * | 35 mln. 25,71 mln. 23,64 mln. | Omzet 2025 * | 38,7 mln. 28,43 mln. 26,14 mln. | Marktkapitalisatie | 104 mln. 76,59 mln. 70,44 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | 2,98 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 2,69 x |
K/w-verhouding 2024 * |
19,1
x | K/w-verhouding 2025 * |
16,1
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 60,46% |
Recentste transcriptie over BioSyent Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
René C. Goehrum
CEO | Chief Executive Officer | 64 | 01-01-96 |
Robert March
DFI | Director of Finance/CFO | - | 10-09-18 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 01-05-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Sara Elford
BRD | Director/Board Member | 53 | 08-01-18 |
René C. Goehrum
CEO | Chief Executive Officer | 64 | 01-01-96 |
Peter Lockhard
BRD | Director/Board Member | 60 | 01-06-02 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+32,09% | 693 mld. | |
+29,39% | 584 mld. | |
-1,34% | 372 mld. | |
+20,34% | 332 mld. | |
+7,39% | 294 mld. | |
+13,74% | 239 mld. | |
-3,03% | 211 mld. | |
+10,02% | 210 mld. | |
+8,49% | 168 mld. |